Appendix G. ACIP Recommendations Prescribing Child Immunization Practices

Under § 89.806(a) (relating to coverage of child immunizations), the Department of Health has established a list of citations to recommendations of the Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, United States Department of Health and Human Services. The child immunization practices specified in those recommendations are subject to the insurance coverage required by the Childhood Immunization Insurance Act (act) (40 P. S. § § 3501—3508) as explained in § 89.806(a).

ACIP recommendations prescribing immunization practices are published in the Morbidity and Mortality Weekly Report (MMWR), a weekly publication of the United States Department of Health and Human Services. MMWR citations to the relevant ACIP recommendations are listed in this appendix. The effective date of insurance coverage required by the act for each ACIP recommended child immunization practice can be ascertained by consulting § 89.806(c).

If new ACIP recommendations that satisfy the standards in § 89.806(a) are published in the MMWR, they will become effective upon publication in the MMWR. The Department of Health will arrange for an update notice to appear in the Pennsylvania Bulletin within 30 days after the MMWR publication date of each future ACIP recommendation that satisfies the standards in § 89.806(a). The new recommendations will be codified in this appendix.

(1) ‘‘General Recommendations on Immunizations,’’ MMWR, January 28, 1994/Vol. 43/No. RR-1, pages 1—38.

(2) ‘‘Diphtheria, Tetanus, and Pertussis: Recommendations for Vaccine Use and Other Preventive Measures,’’ MMWR, August 8, 1991/Vol. 40/No. RR-10, pages 1—28, with the exception of materials relating to Diphtheria Antitoxin.

(3) ‘‘Pertussis Vaccination: Acellular Pertussis Vaccine for Reinforcing and Booster Use-Supplementary ACIP Statement,’’ MMWR, February 7, 1992/Vol. 41/No. RR-1, pages 1—10.

(4) ‘‘Pertussis Vaccination: Acellular Pertussis Vaccine for the Fourth and Fifth Doses of the DTP Series—Update to Supplementary ACIP Statement,’’ MMWR, October 9, 1992/Vol. 41/No. RR-15, pages 1—5.

(5) ‘‘Measles Prevention: Recommendations of the Immunization Practices Advisory Committee,’’ MMWR, December 29, 1989/Vol. 38/No. S-9, pages 1—13.

(6) ‘‘Mumps Prevention,’’ MMWR, June 9, 1989/Vol. 38/No. 22, pages 388—392, 397—400.

(7) ‘‘Rubella Prevention,’’ MMWR, November 23, 1990/Vol. 39/No. RR-15, pages 1—18.

(8) ‘‘Poliomyelitis Prevention,’’ MMWR, January 29, 1982/Vol. 31/No. 3, pages 22—26, 31—34.

(9) ‘‘Poliomyelitis Prevention: Enhanced-Potency Inactivated Poliomyelitis Vaccine—Supplementary Statement,’’ MMWR, December 11, 1987/Vol. 36/No. 48, pages 795—798.

(10) ‘‘Haemophilus b Conjugate Vaccines for Prevention of Haemophilus influenzae Type b Disease Among Infants and Children Two Months of Age and Older,’’ MMWR, January 11, 1991/Vol. 40/No. RR-1, pages 1—7.

(11) ‘‘Recommendations for Use of Haemophilus b Conjugate Vaccines and a Combined Diphtheria, Tetanus, Pertussis, and Haemophilus b Vaccine,’’ MMWR, September 17, 1993/Vol. 42/No. RR-13, pages 1—15.

(12) ‘‘Meningococcal Vaccines,’’ MMWR, May 10, 1985/Vol. 34/No. 18, pages 255—259.

(13) ‘‘Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination,’’ MMWR, November 22, 1991/Vol. 40/No. RR-13, pages 1—25.

(14) ‘‘Protection Against Viral Hepatitis,’’ MMWR, February 9, 1990/Vol. 39/No. RR-2, pages 1—21.

(15) ‘‘Update: Recommendations to Prevent Hepatitis B Virus Transmission—United States,’’ MMWR, August 9, 1995/Vol. 44/No. 30, pages 574—575.

(16) ‘‘Prevention and Control of Influenza,’’ MMWR, May 3, 1996/Vol. 45/No. RR-5, pages 1—24.

(17) ‘‘Pneumococcal Polysaccharide Vaccine,’’ MMWR, February 10, 1989/Vol. 38/No. 5, pages 64-68, 73—76.

(18) ‘‘Rabies Prevention-United States, 1991,’’ MMWR, March 22, 1991/Vol. 40/No. RR-3, pages 1—19.

(19) ‘‘Varicella-Zoster Immune Globulin for the Prevention of Chickenpox,’’ MMWR, February 24, 1984/Vol. 33/No. 7, pages 84—90, 95—100.

(20) ‘‘Prevention of Varicella,’’ MMWR, July 12, 1996/Vol. 45/No. RR-11, pages 1—25.

(21) ‘‘Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among Infants and Young Children,’’ MMWR, March 28, 1997/Vol. 46/No. RR-7.

(22) ‘‘Prevention of Pneumococcal Disease,’’ MMWR, April 4, 1997/Vol. 46/No. RR-8.

(23) ‘‘Measles, Mumps, and Rubella—Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps,’’ MMWR, May 22, 1998/Vol. 47/No. RR-8.

(24) ‘‘Human Rabies Prevention—United States, 1999,’’ MMWR, January 8, 1999/Vol 48/No. RR-1.

(25) ‘‘Prevention of Varicella Updated,’’ MMWR, May 28, 1999/Vol. 48/No. RR-6.

(26) ‘‘Prevention of Hepatitis A Through Active or Passive Immunization,’’ MMWR, October 1, 1999/Vol. 48/No. RR-12.

(27) ‘‘Poliomyelitis Prevention in the United States,’’ MMWR, May 19, 2000/Vol. 49/No. RR-5.

(28) ‘‘Prevention and Control of Meningococcal Disease and Meningococcal Disease and College Students,’’ MMWR, June 30, 2000/Vol. 49/No. RR-7.

(29) ‘‘Preventing Pneumococcal Disease Among Infants and Young Children,’’ MMWR, October 6, 2000/Vol. 49/No. RR-9.

(30) ‘‘Use of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose Series,’’ MMWR, November 17, 2000/Vol. 39/No.13.

(31) ‘‘Prevention and Control of Influenza,’’ MMWR, April 20, 2001/Vol 50/No. RR-4.

(32) ‘‘Notice to Readers: FDA Approval for a Combined Hepatitis A and B Vaccine,’’ MMWR, September 21, 2001 /Vol. 50 / No.37.

(33) ‘‘Simultaneous Administration of Varicella Vaccine and Other Recommended Childhood Vaccines—United States, 1995-1999,’’ MMWR, November 30, 2001 / Vol. 50 / No.47.

(34) ‘‘General Recommendations on Immunization,’’ MMWR, February 8, 2002 / Vol. 51 / No. RR-2.

(35) ‘‘Prevention and Control of Influenza,’’ MMWR, April 12, 2002 / Vol. 51 / No.RR-3.

(36) ‘‘Notice to Readers: Resumption of Routine Schedule for Tetanus and Diphtheria Toxoids,’’ June 21, 2002/Vol. 51/No. 24.

(37) ‘‘Notice to Readers: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children—United States, 2002,’’ July 5, 2002/Vol. 51/No. 26.

(38) ‘‘Notice to Readers: Resumption of Routine Schedule for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine and for Measles, Mumps, and Rubella Vaccine,’’ July 12, 2002/Vol. 51/No. 27.

(39) ‘‘Hepatitis B Vaccination Among High-Risk Adolescents and Adults—San Diego, California, 1998—2001,’’ July 19, 2002/Vol. 51/No. 28.

(40) ‘‘National, State, and Urban Area Vaccination Coverage Levels Among Children Aged 19-35 Months—United States, 2001,’’ August 2, 2002/Vol. 51/No. 30.

(41) ‘‘Impact of Vaccine Shortage on Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Coverage Rates Among Children Aged 24 Months—Puerto Rico, 2002,’’ August 2, 2002/Vol. 51/No 30.

(42) ‘‘Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002,’’ November 8, 2002/Vol. 51/No. RR—17.

(43) ‘‘Notice to Readers: Use of Anthrax Vaccine in Response to Terrorism: Supplemental Recommendations of the Advisory Committee on Immunization Practices,’’ November 15, 2002/Vol. 51/No. 45.

(44) ‘‘Update: Influenza Activity—United States, 2002—03 Season,’’ January 17, 2003/Vol. 52/No. 2.

(45) ‘‘Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991—2001,’’ January 24, 2003/Vol. 52/No. SS—1.

(46) ‘‘Pneumococcal Vaccination for Cochlear Implant Candidates and Recipients: Updated Recommendations of the Advisory Committee on Immunization Practices,’’ August 8, 2003/Vol. 52/No. 31.

(47) ‘‘Notice to Readers: Supplemental Recommendations About the Timing of Influenza Vaccination, 2003-04 Season,’’ August 22, 2003/Vol. 52/No. 33.

(48) ‘‘Notice to Readers: FDA Approval of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, (INFANRIX®) for Fifth Consecutive DTaP Vaccine Dose,’’ September 26, 2003/Vol. 52/No. 38.

(49) ‘‘Notice to Readers: Revised Standards for Adult Immunization Practices and Child and Adolescent Immunization Practices, 2003,’’ October 10, 2003/Vol. 52/No. 40.

(50) ‘‘Notice to Readers: Limited Supply of Pneumococcal Conjugate Vaccine,’’ December 19, 2003/Vol. 52/No. 50.

(51) ‘‘Recommended Childhood and Adolescent Immunization Schedule—United States, January—June 2004,’’ January 16, 2004/Vol. 52/No. 1.

(52) ‘‘Tiered Use of Inactivated Influenza Vaccine in the Event of a Vaccine Shortage,’’ August 5, 2005/Vol. 54/No. 30.

(53) ‘‘National, State, and Urban Area Vaccination Coverage Among Children Aged 19-35 Months—United States, 2004,’’ July 29, 2005/Vol. 54/No. 29.

(54) ‘‘Notice to Readers: Satellite Broadcast on Immunization Update 2005,’’ July 1, 2005/Vol. 54/No. 25.

(55) ‘‘Prevention and Control of Meningococcal Disease: Recommendations of the ACIP,’’ July 30, 2005/Vol. 54/No. 21.

(56) ‘‘Notice to Readers: National Infant Immunization Week—April 24 through 30, 2005,’’ April 15, 2005/Vol. 54/No. 14.

(57) ‘‘Update: Influenza Activity—United States, 2004-05 Season Notice to Readers,’’ April 8, 2005/Vol. 54/No. 13.

(58) ‘‘Estimated Influenza Vaccination Coverage Among Adults and Children—United States, September 1, 2004, through January 31, 2005,’’ April 1, 2005/Vol. 54/No. 12.

(59) ‘‘Hepatitis A Vaccination Coverage Among Children Aged 24-35 Months—United States, 2003’’ February 18, 2005/Vol. 54/No. 6.

(60) ‘‘Notice to Readers: Improved Supply of Meningococcal Conjugate Vaccine, Recommendation to Resume Vaccination of Children Aged 11—12 Years,’’ November 3, 2006/Vol. 55/No. 43.

(61) ‘‘Update: Guillain Barr[eacute] Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine—United States, June 2005—September 2006,’’ October 20, 2006/Vol. 55/No. 41.

(62) ‘‘Pertussis Outbreak in an Amish Community—Kent County, Delaware, September 2004—February 2005,’’ August 4, 2006/Vol. 55/No. 30.

(63) ‘‘Varicella Outbreak Among Vaccinated Children—Nebraska, 2004,’’ August 4, 2006/Vol. 55/No. 30.

(64) ‘‘Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist®) to Children Aged 2—4 Years and Other FluMist Changes for the 2007-2008 Influenza Season,’’ November 23, 2007/Vol. 56/No. 46.

(65) ‘‘Update: Prevention of Hepatitis A After Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP),’’ October 19, 2007/Vol. 56/No. 41.

(66) ‘‘Notice to Readers: FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine (Twinrix®),’’ October 12, 2007/Vol. 56/No. 40.

(67) ‘‘Influenza Vaccination Coverage Among Children Aged 6—23 Months—United States, 2005-2006 Influenza Season,’’ September 21, 2007/Vol. 56/No. 37.

(68) ‘‘Influenza Vaccination Coverage Among Children Aged 6—59 Months—Six Immunization Information System Sentinel Sites, 2006-2007 Influenza Season’’

(69) ‘‘National, State, and Local Area Vaccination Coverage Among Children Aged 19—35 Months—United States, 2006,’’ August 31, 2007/Vol. 56/No. 34.

(70) ‘‘National Vaccination Coverage Among Adolescents Aged 13—17 Years—United States, 2006.’’

(71) ‘‘Notice to Readers: Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11—18 Years with Meningococcal Conjugate Vaccine,’’ August 10, 2007/Vol. 56/No. 31.

(72) ‘‘Hepatitis A Vaccination Coverage Among Children Aged 24—35 Months—United States, 2004-2005,’’ July 13, 2007/Vol. 56/No. 27.

(73) ‘‘Newborn Hepatitus B Vaccination Coverage Among Children Born January 2003—June 2005—United States’’ August 1, 2008/Vol. 57/No. 30.

(74) ‘‘Prevention and Control of Influenza’’ August 8, 2008/Vol. 57/No. RR07.

(75) ‘‘Update: Measles—United States, January—July 2008’’ August 22, 2008/Vol. 57/No. 33.

(76) ‘‘National, State and Local Area Vaccination Coverge Among Children Aged 19—35 Months’’ September 5, 2008/Vol. 57/No. 35.

(77) ‘‘Influenza Vaccination Coverage Among Children Aged 6—59 Months—Eight Immunization Information System Sentinel Sites, United States, 2007-08 Influenza Season’’ September 26, 2008/Vol. 57/No. 38.

(78) ‘‘State-Specific Influenza Vaccination Coverage Among Adults United States, 2006-07 Influenza Season’’ September 26, 2008/Vol. 57/No. 38.

(79) ‘‘Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, and Haemophilus b Conjugate Vaccine and Guidance for Use in Infants and Children’’ October 3, 2008/Vol. 57/No. 39.

(80) ‘‘Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose’’ October 3, 2008/Vol. 57/No. 39.

(81) ‘‘Updated Recommendations for Isolation of Persons with Mumps’’ October 10, 2008, Vol. 57/No. 40.

(82) ‘‘Vaccination Coverage Among Adolescents Aged 13—17 Years—United States, 2007’’ October 10, 2008/Vol. 57/No. 40.

(83) ‘‘Rotavirus Surveillance—Worldwide, 2001—2008’’ November 21, 2008/Vol. 57/No. 46.

(84) ‘‘Continued Shortage of Haemophilus influenzae Type b (Hib) Conjugate Vaccines and Potential Implications for Hib Surveillance—Unites States, 2008’’/Vol. 57/No. 46.

(85) ‘‘Implementation of Newborn Hepatitis B Vaccination—Worldwide, 2006’’/November 21, 2008/Vol. 57/No. 46.

(86) ‘‘Progress in Global Measles Control and Mortality Reduction, 2000—2007’’/December 5, 2008/Vol. 57/No. 48.

(87) ‘‘Evaluation of Rapid Influenza Diagnostic Tests for Detection of Novel Influenza a (H1N1) Virus—United States, 2009’’/August 7, 2009/Vol. 58/No. 30.

(88) ‘‘Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination’’/August 7, 2009/Vol. 58/No. 30.

(89) ‘‘National, State, and Local Area Vaccination Coverage Among Children Aged 19—35 Months—United States, 2008’’/August 28, 2009/Vol. 58/No. 33.

(90) ‘‘Surveillance for Pediatric Deaths Associated with 2009 Pandemic Influenza A (H1N1) Virus Infection—United States, April—August 2009’’/September 4, 2009/Vol. 58/No. 34.

(91) ‘‘Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infection in Two Summer Campers Receiving Prophylaxis—North Carolina, 2009’’/September 11, 2009/Vol. 58/No. 35.

(92) ‘‘National, State, and Local Area Vaccination Coverage Among Adolescents Aged 13—17 Years—United States, 2008’’/September 18, 2009/Vol. 58/No. 36.

(93) ‘‘Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Hepatitis A Vaccine in Close Contacts of Newly Arriving International Adoptees’’/September 18, 2009/Vol. 58/No. 36.

(94) ‘‘Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine’’/September 18, 2009/Vol. 58/No. 36.

(95) ‘‘Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease’’/September 25, 2009/Vol. 58/No. 37.

(96) ‘‘Influenza Vaccination Coverage Among Children Aged 6—23 Months—United States, 2007—08 Influenza Season’’/October 2, 2009/Vol. 58/No. 38.

(97) ‘‘Influenza Vaccination Coverage Among Children and Adults—United States, 2008—09 Influenza Season’’/October 9, 2009/Vol. 58/No. 39.

(98) ‘‘Norovirus Outbreaks on Three College Campuses—California, Michigan and Wisconsin, 2008’’/October 9, 2009/Vol. 58/No. 39.

(99) ‘‘Reduction in Rotavirus After Vaccine Introduction—United States, 2000—2009’’/October 23, 2009/Vol. 58/No. 41.

(100) ‘‘Effectiveness of 2008—09 Trivalent Influenza Vaccine Against 2009 Pandemic Influenza A (H1N1)—United States, May—June 2009’’/November 13, 2009/Vol. 58/No. 44.

(101) ‘‘Mumps Outbreak—New York, New Jersey, Quebec, 2009’’/November 20, 2009/Vol. 58/No. 45.

(102) ‘‘Safety of Influenza A (H1N1) 2009 Monovalent Vaccines—United States, October 1—November 24, 2009’’/December 11, 2009’’/Vol. 58/No. 48.

(103) ‘‘Recommended Adult Immunization Schedule—United States, 2010’’/January 15, 2010/Vol. 59(01)/1-4.

(104) ‘‘Update: Influenza Activity—United States, August 30, 2009-January 9, 2010’’/January 22, 2010/Vol. 59(02)/38-43.

(105) ‘‘Update: Mumps Outbreak—New York and New Jersey, June 2009-January 2010’’/February 12, 2010/Vol. 59(05)/125-129.

(106) ‘‘Progress in Immunization Information Systems—United States, 2008’’/February 12, 2010/Vol. 59(05)/133-135.

(107) ‘‘Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children-Advisory Committee on Immunization Practices (ACIP), 2010’’/March 12, 2010/Vol. 59(09)/258-261.

(108) ‘‘Prevnar 13 Licensure’’/March 12, 2010/Vol. 59(09)/258-261.

(109) ‘‘Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for Use Advisory Committee on Immunization Practices (ACIP), 2010’’/March 12, 2010/Vol. 59(09)/273.

(110) ‘‘2009 Pandemic Influenza A (H1N1) in Pregnant Women Requiring Intensive Care—New York City, 2009’’/March 26, 2010/Vol 59(11)/321-326.

(111) ‘‘Interim Results: State-Specific Influenza A (H1N1) 2009 Monovalent Vaccination Coverage—United States, October 2009 to January 2010’’/April 2, 2010/Vol. 59(12)/363-368.

(112) ‘‘Interim Results: State-Specific Seasonal Influenza Vaccination Coverage—United States, August 2009 to January 2010’’/April 30, 2010/Vol. 59(16)/477-484.

(113) ‘‘FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)’’/May 28, 2010/Vol. 59(20)/626-629.

(114) ‘‘FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)’’/May 28, 2010/Vol. 59(20)/630-632.

(115) ‘‘Preliminary Results: Surveillance for Guillain-Barr[eacute] Syndrome After Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine—United States, 2009-2010’’/June 4, 2010/Vol. 59(21)/657-661.

(116) ‘‘Addition of Severe Combined Immunodeficiency as a Contraindication for Administration of Rotavirus Vaccine’’/June 11, 2010/Vol. 59(22)/687-688.

(117) ‘‘Hepatitis A Vaccination Coverage Among U.S. Children Aged 12-23 Months—Immunization Information System Sentinel Sites, 2006-2009’’/July 2, 2010/Vol. 59/No. 25.

(118) ‘‘Seasonal Influenza Vaccination Coverage Among Children Aged 6 Months-18 Years—Eight Immunization Information System Sentinel Sites, United States, 2009-10 Influenza Season’’/October 8, 2010/Vol. 59/No. 39.

(119) ‘‘Prevention of Pneumococcal Disease Among Infants and Children—Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine’’/December 10, 2010/Vol. 59/No. RR11.

(120) ‘‘Updated Recommendations for Use of Meningococcal Conjugate Vaccines-Advisory Committee on Immunization Practices (ACIP), 2010’’/January 28, 2011/Vol. 60/No. 3.

(121) ‘‘Recommended Immunization Schedules for Persons Aged 0 Through 18 Years—United States, 2011’’/February 11, 2011/Vol. 60/No. 5.

(122) ‘‘Measles Imported by Returning U.S. Travelers Aged 6-23 Months, 2001-2011’’/April 8, 2011/Vol. 60/No. 1.

(123) ‘‘Measles-United States, January-May 20, 2011’’/May 27, 2011/Vol. 60/No. 20.

(124) ‘‘Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease—Advisory Committee on Immunization Practices (ACIP), 2011’’/August 5, 2011/Vol. 60/No. 30.

(125) ‘‘National and State Vaccination Coverage Among Adolescents Aged 13 Through 17 Years—United States, 2010’’/August 26, 2011/Vol. 60/No. 33.

(126) ‘‘National and State Vaccination Coverage Among Children Aged 19-35 Months—United States, 2010’’/September 2, 2011/Vol. 60/No. 34.

(127) ‘‘Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease’’/October 14, 2011/Vol. 60/No. 40.

(128) ‘‘Invasive Pneumococcal Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged ‹=59 Months—Selected United States Regions, 2010-2011’’/November 4, 2011/Vol. 60/No. 43.

(129) ‘‘Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2012-13 Influenza Season’’/August 17, 2012/Vol. 61/No. 32.

(130) ‘‘National and State Vaccination Coverage Among Adolescents Aged 13-17 Years—United States, 2011’’/August 31, 2012/Vol. 61/No. 34.

(131) ‘‘Vaccination Coverage Among Children in Kindergarten—United States, 2011-12 School Year’’/August 24, 2012/Vol. 61/No. 33.

(132) ‘‘National, State, and Local Area Vaccination Coverage Among Children Aged 19-35 Months—United States, 2011’’/September 7, 2012/Vol. 61/No. 35.

(133) ‘‘Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)’’/March 22, 2013/Vol. 62/No. RR02.

(134) ‘‘Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6—18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)’’/June 28, 2013/Vol. 62/No. 25.

Source

The provisions of this Appendix G adopted February 3, 1995, effective February 4, 1995, 25 Pa.B. 511; amended August 16, 1996, effective August 17, 1996, 26 Pa.B. 3958; amended August 10, 2001, effective August 11, 2001, 31 Pa.B. 4498; amended October 25, 2002, effective October 26, 2002, 32 Pa.B. 5352; amended March 14, 2003, effective March 15, 2003, 33 Pa.B. 1418; amended April 16, 2004, effective April 17, 2004, 34 Pa.B. 2135; amended September 17, 2004, effective September 18, 2004, 34 Pa.B. 5218; amended September 16, 2005, effective September 17, 2005, 35 Pa.B. 5190; amended January 19, 2007, effective January 20, 2007, 37 Pa.B. 372; amended December 21, 2007, effective December 22, 2007, 37 Pa.B. 6851; amended February 27, 2009, effective February 28, 2009, 39 Pa.B. 1167; amended February 5, 2010, effective February 6, 2010, 40 Pa.B. 760; amended September 17, 2010, effective September 18, 2010, 40 Pa.B. 5404; amended March 4, 2011, effective March 5, 2011, 41 Pa.B. 1263; amended October 28, 2011, effective October 29, 2011, 41 Pa.B. 5821; amended April 6, 2012, effective April 7, 2012, 42 Pa.B. 1929; amended February 1, 2013, effective February 2, 2013, 43 Pa.B. 745; amended October 11, 2013, effective October 12, 2013, 43 Pa.B. 6079. Immediately preceding text appears at serial pages (311232), (296147) to (296148), (342055) to (342056), (356173) to (356174) and (365547).

Cross References

This appendix cited in 31 Pa. Code § 89.806 (relating to coverage of child immunizations).